"First line weight-loss drug for diabetes: GLP-1 agonist Victoza approved for market launch"

On March 6th, Hangzhou Sinobioway Biomedcine Co., Ltd. announced that the cAMP-biased GLP-1 receptor agonist ligand Enoglutide injection has been approved by the National Medical Products Administration, and is suitable for long-term weight management in adult overweight/obese patients on the basis of controlling diet and increasing physical activity.